These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26241223)

  • 1. The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research.
    Suissa S
    Rambam Maimonides Med J; 2015 Jul; 6(3):. PubMed ID: 26241223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Number needed to treat is incorrect without proper time-related considerations.
    Suissa D; Brassard P; Smiechowski B; Suissa S
    J Clin Epidemiol; 2012 Jan; 65(1):42-6. PubMed ID: 21816576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpreting risk reduction in clinical trials for pulmonary arterial hypertension.
    Lajoie AC; Bonnet S; Lacasse Y; Lega JC; Provencher S
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number needed to treat in COPD: exacerbations versus pneumonias.
    Suissa S
    Thorax; 2013 Jun; 68(6):540-3. PubMed ID: 23125170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Number needed to treat (NNT) in clinical literature: an appraisal.
    Mendes D; Alves C; Batel-Marques F
    BMC Med; 2017 Jun; 15(1):112. PubMed ID: 28571585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Number needed to treat in cardiac rehabilitation.
    Oldridge N; Perkins A; Marchionni N; Fumagalli S; Fattirolli F; Guyatt G
    J Cardiopulm Rehabil; 2002; 22(1):22-30. PubMed ID: 11839993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A note on the number needed to treat.
    Lesaffre E; Pledger G
    Control Clin Trials; 1999 Oct; 20(5):439-47. PubMed ID: 10503803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke.
    Saver JL
    Arch Neurol; 2004 Jul; 61(7):1066-70. PubMed ID: 15262737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants.
    Ohlsson A; Walia R; Shah S
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003481. PubMed ID: 18254020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different adjuvant therapies for 9 resectable cancer types.
    Kruse M; Parthan A; Coombs J; Sasane M; Taylor D
    Postgrad Med; 2013 Mar; 125(2):83-91. PubMed ID: 23816774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of NXY-059 demonstrated in the SAINT I trial: derivation of number needed to treat for benefit over entire range of functional disability.
    Saver JL
    Stroke; 2007 May; 38(5):1515-8. PubMed ID: 17395871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using and Interpreting Adjusted NNT Measures in Biomedical Research.
    Bender R
    Open Dent J; 2010 Jul; 4():72-6. PubMed ID: 20871755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of number needed to treat in cost-effectiveness analyses.
    Garg V; Shen X; Cheng Y; Nawarskas JJ; Raisch DW
    Ann Pharmacother; 2013 Mar; 47(3):380-7. PubMed ID: 23463742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Number Needed to Treat (NNT) as a Measure of Treatment Effect in Respiratory Medicine.
    Cazzola M
    Treat Respir Med; 2006; 5(2):79-84. PubMed ID: 16512688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis.
    Betts TR; Sadarmin PP; Tomlinson DR; Rajappan K; Wong KC; de Bono JP; Bashir Y
    Europace; 2013 Jun; 15(6):813-9. PubMed ID: 23365069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
    Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.